A Phase I/II, Dose-escalation Study of Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis

Trial Profile

A Phase I/II, Dose-escalation Study of Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 May 2017

At a glance

  • Drugs TLC 388 (Primary)
  • Indications Liver cancer; Thrombosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Taiwan Liposome Company
  • Most Recent Events

    • 21 May 2017 Status changed from not yet recruiting to recruiting.
    • 02 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top